<?xml version="1.0" encoding="UTF-8"?>
<p id="par0100">Forty-eight safe-in-man BSAAs undergo clinical studies as antivirals. There are currently 21 compounds in phase I, 34 agents in phase II and 11 compounds in phase III clinical trials. For example, nitazoxanide, remdesivir and brincidofovir are under clinical investigations against different viral infections (NCT03336619, NCT00302640, NCT03605862, NCT03719586, NCT01276756, NCT03905655, NCT01529073, NCT03395405, NCT03216967, NCT01431326, NCT02087306, NCT01769170).</p>
